Evidence map›Paper›PMID 36902332›Full record

ReviewInternational journal of molecular sciences2023

In Search of the Holy Grail: Stem Cell Therapy as a Novel Treatment of Heart Failure with Preserved Ejection Fraction.

Olaf Domaszk, Aleksandra Skwarek, Małgorzata Wojciechowska

Full text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Olaf DomaszkDepartment of Experimental and Clinical Physiology, Center for Preclinical Research, Warsaw Medical University, 02-097 Warsaw, Poland.
Aleksandra SkwarekDepartment of Experimental and Clinical Physiology, Center for Preclinical Research, Warsaw Medical University, 02-097 Warsaw, Poland.
Małgorzata WojciechowskaDepartment of Experimental and Clinical Physiology, Center for Preclinical Research, Warsaw Medical University, 02-097 Warsaw, Poland.ORCID 0000-0003-0995-1171

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure, a leading cause of hospitalizations and deaths, is a major clinical problem. In recent years, the increasing incidence of heart failure with preserved ejection fraction (HFpEF) has been observed. Despite extensive research, there is no efficient treatment for HFpEF available. However, a growing body of evidence suggests stem cell transplantation, due to its immunomodulatory effect, may decrease fibrosis and improve microcirculation and therefore, could be the first etiology-based therapy of the disease. In this review, we explain the complex pathogenesis of HFpEF, delineate the beneficial effects of stem cells in cardiovascular therapy, and summarize the current knowledge concerning cell therapy in diastolic dysfunction. Furthermore, we identify outstanding knowledge gaps that may indicate directions for future clinical studies.

Indexed as

Heart FailureCell- and Tissue-Based TherapyFibrosisHumansStem Cell TransplantationStroke Volumecardiologyheart failurepreserved ejection fractionstem cells

Identifiers

PMID36902332
PMCPMC10003723

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read7
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.